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Abstract
Objective
Benign prostatic hyperplasia (BPH) is the most common proliferative abnormality of the
prostate affecting elderly men throughout the world. Epidemiologic studies have shown that
diabetes significantly increases the risk of developing BPH, although whether anti-diabetic
medications preventing the development of BPH remains to be defined. We have previously
found that stromally expressed insulin-like growth factor 1 (IGF-1) promotes benign prostatic
epithelial cell proliferation through paracrine mechanisms. Here, we seek to understand if
metformin, a first line medication for the treatment of type 2 diabetes, inhibits the prolifera-
tion of benign prostatic epithelial cells through reducing the expression of IGF-1 receptor
(IGF-1R) and regulating cell cycle.
Methods
BPE cell lines BPH-1 and P69, murine fibroblasts3T3 and primary human prostatic fibro-
blasts were cultured and tested in this study. Cell proliferation and the cell cycle were ana-
lyzed by MTS assay and flow cytometry, respectively. The expression of IGF-1R was
determined by western-blot and immunocytochemistry. The level of IGF-1 secretion in cul-
ture medium was measured by ELISA.
Results
Metformin (0.5-10mM, 6-48h) significantly inhibited the proliferation of BPH-1 and P69 cells
in a dose-dependent and time-dependent manner. Treatment with metformin for 24 hours
lowered the G2/M cell population by 43.24% in P69 cells and 24.22% in BPH-1 cells. On the
other hand, IGF-1 (100ng/mL, 24h) stimulated the cell proliferation (increased by 28.81% in
P69 cells and 20.95% in BPH-1 cells) and significantly enhanced the expression of IGF-1R in
benign prostatic epithelial cells. Metformin (5mM) abrogated the proliferation of benign pros-
tatic epithelial cells induced by IGF-1. In 3T3 cells, the secretion of IGF-1 was significantly
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inhibited by metformin from 574.31pg/ml to 197.61pg/ml. The conditioned media of 3T3 cells
and human prostatic fibroblasts promoted the proliferation of epithelial cells and the expres-
sion of IGF-1R in epithelial cells. Metformin abrogated the proliferation of benign prostatic
epithelial cells promoted by 3T3 conditioned medium.
Conclusions
Our study demonstrates that metformin inhibits the proliferation of benign prostatic epithelial
cells by suppressing the expression of IGF-1R and IGF-1 secretion in stromal cells. Metfor-
min lowers the G2/M cell population and simultaneously increases the G0/G1 population.
Findings here might have significant clinical implications in management of BPH patients
treated with metformin.
Introduction
BPH is the most common, proliferative abnormality of the human prostate affecting elderly
men throughout the world. Half of all men, ages 51–60, have histologically identifiable BPH
and by age 85, the prevalence increases to approximately 90% [1]. In the setting when medical
therapy becomes ineffective, prostatectomy by open surgery or transurethral resection of the
prostate is considered the primary method of treatment [2]. However, these surgical treat-
ments are often associated with multiple complications, e.g. urinary tract infection, strictures,
sexual dysfunction, and blood loss. Meanwhile, the underlying molecular alterations that can
potentially be used for targeted therapies are still poorly understood. Further comprehension
of the pathophysiology of BPH and development of a more effective approach would be benefi-
cial to the management of BPH.
Accumulation of epidemiologic evidence demonstrates that BPH is associated with diabetes
mellitus, i.e, diabetes increases the risk of BPH [3]. In 1966, one of the first publications
reported that diabetes was more frequently diagnosed among the patients who subjected to
prostatectomy than those who were not [4]. More recently, in a series of early cross-sectional
studies, Hammarsten’s group reported a direct correlation between insulin levels and annual
BPH growth rates in diabetic patients [5–7]. Other groups further confirmed that hyperinsuli-
nemia and insulin resistance are independent risk factors in BPH development [8, 9].
Together, these studies suggested that BPH is directly associated with diabetes.
Our previous study investigated the molecular mechanism for the development of BPH and
demonstrated that IGF-1 plays a critical role during BPH progression [10]. IGF-1 shares many
similar sequences with insulin, and performs a fundamental role in the regulation of a variety
of cellular processes such as proliferation, differentiation, apoptosis, extracellular matrix
expression, chemotaxis, and neovascularization [11–13]. We have found that IGF-1 regulates
the stromal-epithelial interaction through the paracrine pathway, and also that the activation
of IGF-1R promotes the proliferation of prostatic epithelial cells via MAPK/AKT/cyclin D
pathway [10].
Metformin is a first line medication for type 2 diabetes treatment and has been prescribed
to almost 120 million people worldwide [14]. Interestingly, recent studies have suggested this
medication as a potential anti-proliferative agent. In prostatic cancer cell lines, metformin has
been demonstrated to inhibit cell proliferation and block the cell cycle in the G0/G1 stage by
activating the AMPK pathway [15, 16]. However, the effect of metformin on benign prostatic
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cells still remains unclear. Here, we show that metformin inhibits the proliferation of two
benign prostatic epithelial cell lines, BPH-1 and P69, in a dose-dependent and time-dependent
manner. We show that the administration of metformin lowers the G2/M cell population in
both cell lines and abrogated the effect of IGF-1 on cell proliferation. Finally, we demonstrate
that both the secretion of IGF-1 in fibroblasts and prostatic epithelial cell proliferation pro-
moted by a conditioned medium (CM) of fibroblasts are inhibited by metformin. Our findings
suggest that beyond the treatment of diabetes, metformin can also inhibit the proliferation of
prostate epithelial cells, which may be beneficial to the treatment of BPH.
Materials and methods
Cell culture
Immortalized human benign prostatic epithelial cells, BPH-1 and P69, mouse embryonic
fibroblast 3T3 cells were kindly provided by Drs. Simon Hayward (Vanderbilt University,
Nashville, TN) and Timothy C. Chambers (University of Arkansas for Medical Sciences, Little
Rock, AR), respectively. The cells were maintained in RPMI 1640 (Thermo Scientific, Wal-
tham, MA, USA; for BPH-1and P69) or Dulbecco’s modified Eagle’s medium (DMEM,
Thermo Scientific, Waltham, MA, USA; for 3T3) and supplemented with 2 mmol/L glutamine,
10% fetal bovine serum (FBS), and 1% penicillin-streptomycin at 37˚C with 5% CO2. Human
primary prostatic fibroblast cells were the gift of Dr. Douglas Strand (UT Southwestern Medi-
cal Center, Dallas, TX). Cells were cultured in Stromal Cell Medium SCGM Bullet Kit™
(Lonza, CC-3204 & CC-4181, Walkersville, MD). Conditioned medium (CM) from fibroblast
cells were harvested after 24 hours of culture with or without 5 mM metformin. BPH-1 and
P69 cells were cultured in CM for 24 hours.
Reagents
Antibodies to GAPDH, IGF-1, IGF-1R, pho-IGF-1R, pho-IRS-1(Ser636/639), extracellular sig-
nal-regulated kinase (ERK), pho-ERK(Thr202/Tyr204), pho-AKT (Ser473), AKT, PARP,
cyclin D1, cyclin D2, cyclin D3 and horseradish peroxidase-conjugated secondary antibodies
(goat anti-mouse and goat anti-rabbit) were purchased from Abcam (Cambridge, MA, USA),
Millipore (Billerica, MA, USA), and Cell Signaling (Danvers, MA, USA). Recombinant mouse
IGF-1, anti-human IGF-1 and anti-mouse IGF-1 enzyme-linked immunosorbent assay
(ELISA) kit were obtained from R&D Systems (Minneapolis, MN, USA). MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was
from Promega (Madison, WI, USA).
Cell proliferation assays
Cell proliferation was measured using the MTS assay and Ki-67 immunostaining. The MTS
method was performed in accordance with the manufacturer’s instructions. In brief, MTS sub-
strates were added and incubated for 1 hour at 37˚C. Absorbance was measured at 490 nm by
a microtiter plate reader. Viability of untreated cells was set to 100%, and the absorbance of
wells with only the medium was set to zero. Each experiment was repeated three times. The
nuclear protein Ki-67, an indicator of cell proliferation [17] was used as another marker to
detect cell proliferation by immunofluorescence staining.
Immunostaining
As described previously [18], cells grown on glass coverslips were fixed in 4% paraformalde-
hyde, permeabilized with 0.2% Triton X-100/PBS, and stained with antibodies. The sections
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were counterstained with DAPI and mounted with mounting medium (Vector Lab, Burlin-
game, CA, USA).
Cell cycle assays
We used flow cytometry (BD FACSAria I cell sorter) to assess the population of cells in each
phase. Briefly, cells were trypsinized, washed twice in ice-cold PBS, resuspended in staining
solution (100μg/ml Ribonuclease inhibitor, 100μg/ml propidium iodide solution, 0.1% NP40
in PBS), and finally incubated for 30 minutes in the dark at RT, prior to analysis.
Protein extraction and western-blot
The complete cell lysates were harvested on ice with M-PER protein extraction reagent
(Thermo Scientific, Waltham, MA, USA) containing a mixture of protease and phosphate
inhibitors (Thermo Scientific, Waltham, MA, USA). After sonication for 10 seconds, cell
debris was removed by centrifugation (12,000g) for 10 minutes at 4˚C. The protein concentra-
tion was determined by BCA protein assay reagent (Pierce, Rockford, IL, USA). A total of
50ng of protein per lane was supplemented with loading buffer (NuPage; Invitrogen, Carlsbad,
CA, USA) and boiled for 10 minutes. Immunoblotting was performed as previously described
[18]. The cell lysates were subjected to 8%-16% Bis-Tris gels (Invitrogen, Carlsbad, CA, USA)
and transferred onto PVDF membranes (Millipore, Billerica, MA, USA). Membranes were
probed with target antibodies.
ELISA
An ELISA kit for IGF-1 was purchased from R&D Systems Inc. (catalog no. MG100), and was
used throughout the experiments. The assays were performed in accordance with the instruc-
tions of the manufacturer. After completion of the ELISA assay, luminescence was assayed by
a plate reader at 450 nm.
Statistical analyses
The experimental results were presented as mean ± standard error of the mean of replicate
analysis accompanied by the number of independent experiments. Statistical analyses were
performed using the student’s t-test. A p value of less than 0.05 was considered statistically
significant.
Results
Metformin inhibits the proliferation of BPH epithelial cells
To investigate the effects of metformin on the proliferation of benign prostate cells, P69 and
BPH-1 cells were first maintained in serum-starved conditions for 12 hours. This was followed
by the administration of metformin at a concentration of 0.5, 1, 5, or 10 mM. After 24 hours of
exposure, a significantly decreased cell viability was observed with escalating doses of metfor-
min (BPH-1, Fig 1A and P69, Fig 1B). Next, P69 and BPH-1 cells were treated with metformin
(5 mM) over a 48 hour period. The MTS test showed that metformin inhibited the prolifera-
tion of both cell lines in a time-dependent manner (Fig 1C and 1D). The treatment of metfor-
min at 5 mM for 48 hours significantly inhibited the cell growth in both cell lines (p<0.001).
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Metformin inhibits IGF-1-induced cell growth of BPH-1 and P69
Since it has been well established that locally enforced IGF-1 expression induces hyperplasia in
the prostate [19] [14], we next sought to determine whether metformin regulates cell growth
when promoted by IGF-1. As expected, pre-treatment of IGF-1 (100 ng/mL) for 24 hours sig-
nificantly stimulated the proliferation of BPH-1 (Fig 2A) and P69 cells (Fig 2B). Furthermore,
the administration of metformin completely abrogated IGF-1 (100 ng/mL) induced growth in
BPH-1(Fig 2A, 2C and 2E) and P69 cells (Fig 2B, 2D and 2F). To further confirm this finding,
we evaluated the expression of the proliferative marker, Ki-67, in BPH-1 and P69 cells [17].
We found that metformin markedly decreased the number of Ki-67 positive cells in the BPH-1
(Fig 2C and 2E) and P69 cell lines (Fig 2D and 2F) either with or without IGF-1 treatment.
Findings here suggest that metformin inhibits the proliferation of benign prostate epithelial
cells, and this effect may be associated with the IGF-1 axis.
Metformin inhibits the expression of IGF-1R and abrogates IGF-
1-induced phosphorylation of IGF-1R
Previously we have shown that IGF-1 signaling plays a critical role in the progression of BPH
and also that cyclin D is the main target of IGF-1 signaling pathway [10]. Others have demon-
strated the effect of metformin on cell growth is cyclin D-dependent but not mediated by
Fig 1. Metformin inhibits human benign prostatic epithelial cell growth. A-B: Cell viability of BPH-1 (A) and P69 (B)
24 hours after treatment with various doses of metformin. MTS test was performed as described in Materials and Methods.
The results are expressed as percent of viable cells compared with control group. C-D: Cell viability of BPH-1 (C) and P69
(D) after the treatment of 5 mM metformin in different times. *, P<0.05; **, P<0.001 compared with control group.
doi:10.1371/journal.pone.0173335.g001
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AMPK [15]. We next asked the question if metformin could regulate the activation of IGF-1R.
We found that the protein level of pho-IGF-1R was significantly decreased in BPH-1 cells
upon the treatment of metformin in a time- and dose-dependent manner (Fig 3A). Metformin
also inhibited the phosphorylation of IRS-1, which is one of the primary substrates of IGF-1R
(Fig 3A). The ratios of pho-IGF-1R to IGF-1R and pho-IRS-1 to GAPDH were decreased 30 to
100-fold in metformin-treated BPH-1 cells when compared with the untreated control cells
(Fig 3B and 3C). Similar results were obtained in P69 cells (data not shown). Furthermore, we
observed that metformin not only inhibited the original expression of pho-IGF-1R on BPH-1
(Fig 3D upper panel and Fig 3F) and P69 cells (Fig 3E upper panel and Fig 3G), but also signifi-
cantly inhibited the IGF-1-stimulated pho-IGF-1R expression (Fig 3D lower panel and Fig 3E
Fig 2. Metformin inhibits IGF-1-induced growth of BPH-1 and P69 cells. A-B: Cell viability (MTS test) of
BPH-1 (A) and P69 (B) 24 hours after treatment of 100 ng/mL IGF-1 with/without 5 mM metformin. C-D:
Representative picture of Ki-67 staining in BPH-1 (C) and P69 (D) cells 24 hours after treatment of 100 ng/mL
IGF-1 with/without 5 mM metformin. E-F: Quantification of Ki-67 staining in BPH-1 (E) and P69 (F). *, P<0.05
compared with the control group; #, P<0.05 compared with the IGF-1 group. CTR: non-treated control, Met:
metformin.
doi:10.1371/journal.pone.0173335.g002
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lower panel). Together, we speculate that metformin inhibits prostate epithelial cell growth via
preventing the IGF-1R expression through autocrine or paracrine mechanisms.
Metformin inhibits the expression of cell proliferating regulators Erk and
Akt
The Erk pathway plays an important role in cell differentiation, proliferation and apoptosis
[20, 21], and also has a stimulating effect on BPH development [22]. To examine the effects of
metformin on the downstream signaling pathway of IGF-1 in prostate epithelial cell growth,
we next evaluated the protein levels of pho-Erk and pho-Akt in metformin-treated BPH-1
cells. We observed the decreased phosphorylation of Erk protein, in the wake of increased
doses of metformin (Fig 4A). The administration of metformin (5 mM) for 48 hours to BPH-1
cells induced 4-fold decrease of pho-Erk expression (Fig 4C). We next determined the level of
Fig 3. Metformin inhibits expression of IGF-1 receptor (IGF-1R) and abrogates IGF-1-induced phosphorylation of IGF-1R. A:
Immunoblotting of IGF-1R, pho-IGF-1R and pho-IRS-1 in proliferating BPH-1 cells treated with various doses of metformin for 24 hours,
or with 5 mM metformin for the indicated times. B-C: Quantification of the immunoblot protein expression of pho-IGF-1R (B) and pho-
IRS-1 (C) in BPH-1 cells treated with 5 mM Metformin for 24 hours, and normalized to IGF-1R or GAPDH, respectively. **, P<0.001
compared with control group. D-E: Representative immunofluorescence images of pho-IGF-1R in BPH-1 (D) and P69 (E) cells after
exposure to 100 ng/mL IGF-1 in the presence or absence of 5 mM metformin for 48 hours. F-G: Immunoblotting of pho-IGF-1R and pho-
IRS-1 in BPH-1 (F) and P69 (G) cells 48 hours after treatment of IGF-1(100 ng/mL) and metformin (5 mM). CTR: untreated control, Met:
metformin.
doi:10.1371/journal.pone.0173335.g003
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Akt, another key regulator for cell cycle, cellular proliferation and apoptosis. As expected, we
found a significant decrease of pho-Akt protein level upon the treatment of metformin (Fig 4B
and 4D). This observation is in line with other studies which have shown that IGF-1 is a key
activator of Akt [23, 24]. Overall, our data suggests that metformin inhibits the prostate epithe-
lial cell growth at least partly through the Erk and Akt signaling pathway.
Metformin regulates the cell cycle and the expression of cyclin D
Following our findings that metformin affects on the expression of pho-Akt and pho-Erk, we
further investigated if cyclin D1, D2 and D3, proteins active in controlling the cell cycle and in
initiating DNA synthesis, are modulated. We found that in BPH-1 cells, the main targets for
both Akt and Erk pathways in the process of cell cycle [10, 25, 26] were significantly reduced
by treatment with metformin, especially at high concentrations of 5 and 10 mM (Fig 5A).
More importantly, metformin blocked the upregulation of cyclin D1, D2 and D3 induced by
IGF-1 (Fig 5B). We then assumed that metformin affects the cell cycle regulations in prostatic
epithelial cells. To explore this hypothesis, the populations of BPH-1 and P69 cells in different
stages were analyzed by flow cytometry after administration of metformin. We found that
IGF-1 led to significant reduction of cells in the phase of G0/G1 and increasing of cells in the S
and G2/M phases both in BPH-1 (Fig 5C and 5E) and P69 cells (Fig 5D and 5F). Concomitant
administration of metformin blocked the cells in the phase of G0/G1 in the presence of metfor-
min. Simultaneously, the G2/M cell population was decreased from 30.48% to 18.07% in P69
cells (Fig 5D) and from 21.52% to 16.20% in BPH-1 cells (Fig 5C). These results indicate that
metformin prevents the mitotic effects of IGF-1 in prostatic epithelial cells.
Metformin interrupts the effect of stromal cells on epithelial cells
Stromal-epithelial interactions play a critical role in the development of BPH, and also in this
interplay we have seen that IGF-1 acts as a paracrine factor [10, 27, 28]. Therefore, we sought
to determine if metformin regulates this interaction. We found that addition of murine
Fig 4. Metformin inhibits the expression of cell proliferating regulators, Erk and Akt. A-B: Representative
immunoblot of three different experiments of pho-Erk (A) and pho-Akt protein levels (B) in BPH-1 cells 48h after treatment
of metformin. C-D: Quantification of the immunoblot protein levels of pho-Erk (C) and pho-Akt (D) in BPH-1 cells treated
with 5 mM metformin for 48 hours by normalization to GAPDH and Akt, respectively. *, P<0.05, compared with control
group. CTR: control, Met: metformin.
doi:10.1371/journal.pone.0173335.g004
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fibroblast 3T3 CM significantly enhanced the proliferation of BPH-1(Fig 6A) and P69 cells
(Fig 6B). Meanwhile, concomitant metformin-treated CM resulted in similar cell viability to
that of control cells, which were treated with normal control medium (Fig 6A and 6B), indicat-
ing that metformin inhibited the proliferation of epithelial cells induced by fibroblast CM. Fur-
thermore, in 3T3 cells, the secretion of IGF-1 was robustly inhibited by metformin from
574.31pg/ml to 197.61pg/ml (Fig 6C). Finally, we verified the above finding in human prostatic
fibroblast cells. Both IGF-1R and pho-IGF-1R in BPH-1 cells were upregulated when treated
with CM of human prostatic fibroblasts. This change was suppressed by metformin-treated
CM (Fig 6D). Metformin treatment also inhibited the secretion of IGF-1 in human prostatic
fibroblasts (Fig 6F), and inhibited the viability of BPH-1 cells (Fig 6E). Together, we propose
Fig 5. Metformin regulates cell cycle and the expression of proteins regulating cell cycle. A: Representative
immunoblot analysis of cyclin D1, D2 and D3 in BPH-1 cells 48 hours after treatment of indicated dose of metformin.
GAPDH was used as a loading control. B: The effect of 48-hour treatment of 100 ng/mL IGF-1 and 5 mM metformin on the
expression of cyclin D1, D2 and D3 in BPH-1 cells. C-D: Flow cytometry analysis of proliferating BPH-1 (C) and P69 (D)
cells 48 hours after the addition of 100 ng/mL IGF-1, 5 mM metformin or both. E-F: The population of G0/G1 cells in BPH-1
(E) and P69 (F) cells (n = 3). *, P<0.05 compared with the control group; #, P<0.05 compared with the IGF-1 treated group.
CTR: non-treated control, Met: metformin.
doi:10.1371/journal.pone.0173335.g005
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that metformin down-regulates the effect of stromal cells on the proliferation of epithelial cells,
at least partially, via inhibition of the IGF axis.
Discussion
While there are dissenting opinions, the preponderance of the evidence supports the view that
patients with insulin-resistance/type 2 diabetes are at a higher risk of developing BPH and also
various diabetes-associated disorders in the pathogenesis of BPH [29]. Further, epidemiologi-
cal studies demonstrate insulin-resistance as an independent risk factor for BPH development
[7, 8]. Therefore, whether and how the anti-diabetic drug, metformin, affects BPH develop-
ment is an important clinical issue to address. As the first-line of medication for type-2
diabetes, metformin demonstrates the best risk-benefit profile when compared with other
Fig 6. Metformin interrupts the effect of stromal cells on epithelial cells. A-B: The cell viability of BPH-1 (A) and P69
(B) was markedly enhanced with conditioned medium of 3T3 fibroblast cells, and was abrogated by 5 mM metformin. C:
Metformin (5 mM, 24 h) inhibited the secretion of IGF-1 in 3T3 cells. D: Immunoblots of IGF-1R and pho-IGF-1R in BPH-1
cells treated with CM of human prostatic fibroblast. E: The BPH-1 cell viability after treatment with CM of human prostatic
fibroblast. F: Metformin (5 mM, 24 h) inhibited the secretion of IGF-1 in human prostatic fibroblasts. *, P<0.05 compared
with the control (CTR) group; #, P<0.05 compared with CM-treated group. CTR: non-treated control, Met: metformin.
doi:10.1371/journal.pone.0173335.g006
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diabetic drugs. Ours and other recent data further suggest that metformin could inhibit pros-
tate and breast cancer cell proliferation in vitro [15, 30, 31] and reduce the risk of cancer [32]
in vivo, while only moderately inhibiting benign prostatic epithelial cell growth at low concen-
trations (up to 5 mM) [33]. In this study, for the first time, we show that metformin potently
inhibits the proliferation of human benign prostatic epithelial cells in vitro in a dose-depen-
dent (0.5, 1, 5, and 10 mM) and time-dependent (6, 12, 24, and 48h) manner. Furthermore,
we find that IGF-1 is involved in the abrogation of cell proliferation induced by metformin.
Taken together, our data suggest that metformin reduces the proliferation of prostatic epithe-
lial cells.
Meanwhile, it is worthy to investigate the underlying molecular mechanism of metformin
regulating prostatic epithelial cell proliferation. The IGF-1 signaling pathway has been identi-
fied both in normal prostate gland development and in prostatic cancer cell progression and
studies have shown that locally enforced IGF-1 expression induces hyperplasia in the prostate
[19, 34]. In our previous study, we found that stromally secreted IGF-1 stimulates BPH-1 cellu-
lar proliferation via up-regulation of epithelial mitogen-activated protein kinase, Akt, and
cyclin D protein levels, while simultaneous down-regulation of cyclin-dependent kinase inhib-
itor p27. The results suggest that the activation of the IGF-1 axis is critical in prostatic epithelial
cell growth [10]. Here, we provide evidence that metformin down-regulates the IGF-1 axis
through inhibiting the phosphorylation of IGF-1R in a time- and dose-dependent manner.
Moreover, metformin suppressed the activation of IGF-1R stimulated by IGF-1. Collectively,
our data suggest that the suppressive effect of metformin on prostatic epithelial cellular prolif-
eration is at least partially attributed to the suppression of the IGF-1 axis.
Another observation in our study is that the inhibiting effect of metformin on the prolifera-
tion of benign prostatic epithelial cells mainly attributes to the regulation of cell cycle. It has
been shown that the cyclin D family (cyclin D1, D2 and D3), a major regulator of core cell
cycle machinery [15, 25, 35], is a main downstream target of the IGF-1 axis [10, 36–38]. We
have found that BPH-1 cell proliferation was markedly enhanced with over-expression of
cyclin D [10]. Therefore, the IGF-regulated cyclin expression might be a potential molecular
target in order to control BPH development. As shown in Figs 4 and 5, this hypothesis is con-
firmed by the cell cycle blockage in the G0/G1 phase and the inhibition of cyclin protein
expression with the administration of metformin.
Stromal-epithelial interactions play a pivotal role in the regulation of the development and
growth of the prostate. The study of Dong et al. found a 3-fold higher expression of IGF-IR
and a 10-fold higher expression of IGF-II in primary culture of BPH stromal cells when com-
pared with normal stromal cells [39]. In line with previous reports, we have also shown that
stromally secreted IGF-1 could act as a paracrine factor and directly induce the proliferation
and growth of prostatic epithelial cells [10]. Furthermore, here we demonstrate that metformin
decreases the secretion of IGF-1 from the stromal cells and inhibits the proliferation of pros-
tatic epithelial cells in metformin pre-treated CM from stromal cells. These results suggest
that metformin affects the stromal and epithelial cell interactions not only through inhibiting
the expression of IGF-1R and the activation of the IGF-1 axis in the epithelial cells, but also
through regulating the stromally secreted IGF-1. Further investigation of this pathway may be
helpful in the management of lower urinary tract symptoms suffering from BPH in diabetic
patients.
In conclusion, our study provides the first demonstration that metformin significantly
inhibits the proliferation of benign prostatic epithelial cells. We show that metformin lowers
the G2/M cell population and simultaneously increases the G0/G1 population. Furthermore,
we demonstrate that metformin not only inhibits the cell proliferation and IGF-1R expression
activated by IGF-1, but also inhibits the IGF-1 secretion in stromal cells and then suppresses
Metformin inhibits benign prostatic epithelial cells proliferation
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the epithelial cell proliferation with stromal CM. Findings here might have significant clinical
implications in management of BPH patients treated with metformin.
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